Keyphrases
Bladder Cancer
100%
Androgens
100%
Radical Cystectomy
100%
Total Testosterone
100%
Postoperative Day
45%
Psoas muscle
27%
Muscle Cross-sectional Area
27%
Free Testosterone
27%
Androgen Levels
27%
Computed Tomography
18%
Sarcopenia
18%
Operative
18%
Weight Loss
18%
Luteinizing Hormone
18%
No Significant Difference
9%
Newly Diagnosed
9%
Anesthesia
9%
Pre-op
9%
Statistical Analysis
9%
Postoperative Period
9%
Male Patients
9%
Testosterone
9%
Hormonal Profile
9%
Change in Weight
9%
Postoperative Changes
9%
Average Weight
9%
Day of Surgery
9%
Background Prior
9%
Net Change
9%
Prospective Observational Trial
9%
Testosterone Deficiency
9%
Low Testosterone
9%
Metastatic Bladder Cancer
9%
Serum Androgens
9%
AUA Guidelines
9%
L-average
9%
Testosterone Hormone
9%
Medicine and Dentistry
Bladder Cancer
100%
Androgen
100%
Cystectomy
100%
Psoas Muscle
50%
Testosterone
50%
Sarcopenia
33%
Computer Assisted Tomography
33%
Luteinizing Hormone
33%
Malignant Neoplasm
16%
Prevalence
16%
Postoperative Period
16%
Day of Surgery
16%
Androgen Deficiency
16%
Metastatic Bladder Cancer
16%
Carbohydrate Mixture Plus Electrolytes
16%
Pharmacology, Toxicology and Pharmaceutical Science
Androgen
100%
Bladder Cancer
100%
Testosterone
50%
Luteinizing Hormone
33%
Sarcopenia
33%
Malignant Neoplasm
16%
Prevalence
16%
Androgen Deficiency
16%
Carbohydrate Mixture Plus Electrolytes
16%